Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck Licenses Zymeworks Process
by Lisa M. Jarvis
September 5, 2011
| A version of this story appeared in
Volume 89, Issue 36
Merck & Co. will pay up to $187 million for access to bispecific antibody development technology from privately held Zymeworks. A bispecific antibody consists of two different heavy chains engineered into one molecule, enabling binding to two separate drug targets. Vancouver, British Columbia-based Zymeworks will receive an undisclosed up-front fee and research funding and could get regulatory milestones and royalties on any drugs that reach the market.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X